Form 4: RenovoRx Chief Clinical Officer Leesa Gentry Granted Stock Options

Leesa Gentry, Chief Clinical Officer of RenovoRx, Inc., was granted stock options to purchase 26,477 shares of the company's common stock on April 14, 2025.

Summary

• On April 14, 2025, Leesa Gentry, the Chief Clinical Officer of RenovoRx, Inc., received stock options.
• The options allow her to purchase up to 26,477 shares of RenovoRx's common stock.
• The exercise price of the options is $0.8448 per share.
• The options vest over four years, starting January 1, 2025, at a rate of 1/48 per month, with no cliff.
• The options will only become exercisable when there is an effective registration statement covering the underlying shares.
• The options will be fully vested by January 1, 2029, and will expire on April 14, 2035.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. It reflects standard executive compensation practices, incentivizing management. The lack of immediate exercisability tempers any immediate positive impact.

Positives

• The grant of stock options to the Chief Clinical Officer aligns her interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the executive.

Risks

• The options are not exercisable until a registration statement covering the underlying shares is effective, which introduces uncertainty.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting and expiration dates of the options.

Industry Context

Stock options are a common form of executive compensation in the biotechnology industry, aligning management's interests with shareholder value creation.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for executives in publicly traded companies, particularly in the biotech sector.
• Vesting schedules of four years are typical to incentivize long-term performance.
• The specific number of shares and exercise price would need to be compared to similar companies of RenovoRx's size and stage to determine if the grant is within industry norms.

Stakeholder Impact

• Shareholders: The grant aligns executive interests with shareholder value.
• Employees: The grant may motivate other employees through example.
• Management: The grant provides an incentive for long-term performance.

Key Dates

Keywords

stock options, RenovoRx, RNXT, Leesa Gentry, Chief Clinical Officer, equity compensation, Form 4